Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (535)	9/24/1999 3:13:00 PM
From: SteveG	Read Replies (1) \| Respond to of 717

Antrin is being presented in 4 papers at TCT today and tomorrow, which is likely a large part of today's selloff resilient move. PCYC had interest in purchase of over 10MM shares, but didn't want the dilution (or need the cash). with Lutrin considered a given and worth about $25/share, according to HQ's van den Broek (the axe on PCYC), the market is assigning about $15/share (~$225M) to Lutrin, Xcytrin and Optrin as an aggregate. obviously a handicapping play, but any one of these could be worth several multiples of that. and all are thought to be looking pretty strong. Xcytrin presents at ASTRO end of Oct, and possible big news in Nov as Antrin presents at AHA which may include longer-term clinical follow up of Phase I/II data on first 50 patients. "..By AHA, Antrin will have entered advanced clinical trials in peripheral arterial disease, and preliminary clinical trials in cardiovascular disease. Several of the leading cardiologists are signed on to design and run these trials, which should raise the profile of the drug. Additional presentations will detail Antrin's unique mechanism of action..." PCYC has had a great run, but if any or all of these come through, this could be a $100-$500 stock. And handicapping the possibility of that IMO is significantly helped by tuning into very bullish van den Broek. Look for an update by him soon.